October 12, 2017 / 5:53 AM / a year ago

Indian shares inch up; Sun Pharma rises

* NSE index up 0.45 pct, BSE index 0.41 pct higher

* Sun Pharma among top gainers after FDA ends inspection at plant

* Broad-based market consolidation to continue - analyst

By Samantha Kareen Nair

Oct 12 (Reuters) - Indian shares nudged up on Thursday, after having ended lower in the previous session, with Sun Pharmaceutical Industries Ltd jumping to an over-two-month high after the U.S. health regulator closed the inspection of the drug-maker’s Dadra plant.

However, gains were muted ahead of key corporate results including that of Tata Consultancy Services Ltd which will report later in the day. The stock was trading up 1.2 percent.

“Market has been witnessing a broad-based consolidation mode for a few months now which will continue for a while. This earnings season is critical as the first quarter was disappointing and hopes are now pinned to see a recovery in the second quarter,” said Rakesh Tarway, head of research at Reliance Securities.

Meanwhile, India’s inflation data for September will be released later in the day. Consumer inflation is forecast to have risen to 3.60 percent in the month, above August’s 3.36 percent, according to a Reuters poll.

The broader NSE index was up 0.45 percent at 10,029.5 as of 0539 GMT, while the benchmark BSE index was 0.41 percent higher at 31,966.22.

Sun Pharmaceutical Industries Ltd rose as much as 3.6 percent to its highest since July 31. The stock led gains on both indexes and was also the top percentage gainer on the Nifty Pharma index, which was up 1 percent.

The Nifty Realty index was trading up 1.16 percent, boosted mainly by Indiabulls Real Estate Ltd which rose as much as 8 percent after the company said its unit would buy out the remaining stake of Indiabulls Properties Investment Trust and delist the company. bit.ly/2gdf9jQ

Reliance Industries Ltd gained as much as 1.4 percent ahead of its quarterly results slated for Friday. Analysts expect to see higher earnings from the company’s core petrochemicals business, while also pointing to a possible benefit for Reliance’s Jio arm due to lower interconnection charges. (Reporting by Samantha Kareen Nair in Bengaluru; Editing by Sunil Nair)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below